Table 1.
Clinicopathological details
| ITT N = 27 | Per-protocol analysis N = 23 | |
|---|---|---|
| Age (years) | 63.7 (10.5) | 63.3 (9.9) |
| BMI (kg/m2) | 28.1 (6.3) | 28.2 (6.6) |
| Duration of the AI treatment at enrolment (month)a | 21.1 (13.3–37.6) | 21.1 (10.3–35.7) |
| Time between primary diagnosis to metastatic diagnosis (month)a | 60.7 (2.0–116.1) [n = 23] | 60.7 (2.0–105.4) [n = 19] |
| Ethnicity | ||
| White | 24 (88.9%) | 21 (91.3%) |
| Asian | 1 (3.7%) | 1 (4.4%) |
| Black | 1 (3.7%) | 0 (0%) |
| Chinese | 1 (3.7%) | 1 (4.4%) |
| No. of sites of disease | ||
| 1 | 7 (25.9%) | 6 (26.1%) |
| 2 | 9 (33.3%) | 8 (34.8%) |
| 3 | 7 (25.9%) | 7 (30.4%) |
| 4 | 1 (3.7%) | 0 (0%) |
| 5 | 2 (7.4%) | 1 (4.4%) |
| Missing | 1 (3.7%) | 1 (4.4%) |
| Visceral disease | ||
| No | 6 (22.2%) | 6 (26.1%) |
| Yes | 20 (74.1%) | 16 (69.6%) |
| Missing | 1 (3.7%) | 1 (4.4%) |
| ER statusb | ||
| Positive | 27 (100%) | 23 (100%) |
| Negative | 0 (0%) | 0(0%) |
| PgR statusb | ||
| Positive | 20 (74.1%) | 16 (69.6%) |
| Negative | 4 (14.8%) | 4 (17.4%) |
| Unknown | 3 (11.1%) | 3 (13.0%) |
| HER2 statusb | ||
| 0 | 10 (37.0%) | 10 (43.5%) |
| 1+ | 10 (37.0%) | 7 (30.4%) |
| 2+ | 3 (11.1%) | 2 (8.7%) |
| Amplified | 0 (0%) | 0 (0%) |
| 3+c | 1 (3.7%) | 1 (4.4%) |
| Not done | 3 (11.1%) | 3 (13.0%) |
| Treatment history: chemotherapy | ||
| No | 10 (37.0%) | 9 (39.1%) |
| Yes | 17 (63.0%) | 14 (60.9%) |
| Neoadjuvant | 2 (9.1%) | 1 (5.9%) |
| Adjuvant | 14 (63.6%) | 11 (64.7%) |
| Advanced 1st line | 6 (27.3%) | 5 (29.4%) |
| Treatment history: radiotherapy | ||
| No | 13 (48.1%) | 11 (47.8%) |
| Yes | 14 (51.9%) | 12 (52.2%) |
| Adjuvant | 19 (63.3%) | 18 (66.7%) |
| Palliative | 11 (36.7%) | 9 (33.3%) |
| Treatment history: endocrine therapy | ||
| No | 0 (0%) | 0 (0%) |
| Yes | 27 (100.0%) | 23 (100.0%) |
| Neoadjuvant | ||
| Anastrozole | 1 (2.1%) | 1 (2.5%) |
| Adjuvant | ||
| Exemestane | 1 (2.1%) | 1 (2.5%) |
| Letrozole | 1 (2.1%) | 1 (2.5%) |
| Anastrozole | 4 (8.5%) | 3 (7.5%) |
| Tamoxifen | 16 (34.0%) | 13 (32.5%) |
| Advanced 1st line | ||
| Exemestane | 3 (6.4%) | 3 (7.5%) |
| Letrozole | 17 (36.2%) | 14 (35.0%) |
| Anastrozole | 4 (8.5%) | 4 (10.0%) |
ITT intent to treat
Data presented are mean (SD) for continuous variables and frequency (percentage) for categorical variables
aData presented are median (inter quartile range)
bBased on diagnostic biopsy and primary tumour sample
cHER2 results: 3+ on diagnostic biopsy and 1+ on resected tumour